专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100130466A1 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS 失效
标题翻译：三唑基氨基嘧啶化合物
公开(公告)号：US20100130466A1
公开(公告)日：2010-05-27
申请号：US12596957
申请日：2008-05-07
申请人： Harold Burns Brooks , Joyce Z. Crich , Delu Jiang , Hong-Yu Li , William Thomas McMillen , Jason Scott Sawyer , Melissa Kate Slater , Yan Wang , James Robert Henry , Hong Hu , Sachin Govindlal Maniar
发明人： Harold Burns Brooks , Joyce Z. Crich , Delu Jiang , Hong-Yu Li , William Thomas McMillen , Jason Scott Sawyer , Melissa Kate Slater , Yan Wang , James Robert Henry , Hong Hu , Sachin Govindlal Maniar
IPC分类号： A61K31/506 , C07D409/14 , A61P35/00 , C07D413/14 , A61K31/5377
CPC分类号： C07D409/14
摘要： The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
摘要翻译：本发明提供可用于治疗癌症的三唑基氨基嘧啶化合物。

2. 发明授权

US07109229B2 Methods and compounds for treating proliferative diseases 失效
标题翻译：治疗增殖性疾病的方法和化合物
公开(公告)号：US07109229B2
公开(公告)日：2006-09-19
申请号：US10344245
申请日：2001-09-24
申请人： Thomas Albert Engler , Kelly Wayne Furness , Sushant Malhotra , Stephen Lyle Briggs , Harold Burns Brooks , David K yes Clawson , Concepcion Sanchez-Martinez , Faming Zhang , Guoxin Zhu
发明人： Thomas Albert Engler , Kelly Wayne Furness , Sushant Malhotra , Stephen Lyle Briggs , Harold Burns Brooks , David K yes Clawson , Concepcion Sanchez-Martinez , Faming Zhang , Guoxin Zhu
IPC分类号： A61K31/40 , C07D481/00
CPC分类号： C07D403/14 , C07D487/14
摘要： The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).
摘要翻译：本文公开的化合物是式（I）的吲哚并唑，其是有效的CDK4抑制剂，并且可用于治疗包括癌症的细胞增殖性疾病。式（I）。

3. 发明申请

US20100087431A1 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS 失效
公开(公告)号：US20100087431A1
公开(公告)日：2010-04-08
申请号：US12598926
申请日：2008-05-07
申请人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong Hu , Delu Jiang , Hong-Yu Li , William Thomas McMillen , Jason Scott Sawyer , Melissa Kate Slater , Yan Wang
发明人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong Hu , Delu Jiang , Hong-Yu Li , William Thomas McMillen , Jason Scott Sawyer , Melissa Kate Slater , Yan Wang
IPC分类号： A61K31/506 , C07D409/14 , C07D413/14 , A61K31/5377 , A61P35/00
CPC分类号： C07D409/14
摘要： The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

4. 发明授权

US08063212B2 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer 失效
标题翻译：咪唑烷酰氨基嘧啶化合物治疗癌症
公开(公告)号：US08063212B2
公开(公告)日：2011-11-22
申请号：US12516251
申请日：2007-12-11
申请人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong-Yu Li , Jason Scott Sawyer , Yan Wang
发明人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong-Yu Li , Jason Scott Sawyer , Yan Wang
IPC分类号： C07D401/00
CPC分类号： C07D409/14
摘要： The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, morpholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了被认为具有通过抑制Plk1治疗癌症的临床用途的新型咪唑烷基氨基嘧啶化合物。式（I）其中：R1是氨基甲基，（C1-C3烷基）氨基甲基，二（C1-C2烷基）氨基甲基，N-乙基-N-甲基 - 氨基甲基，1-氨基乙基，1-（（C1-C2烷基）氨基）乙基，3,3,3-三氟 - 丙氨基甲基，乙炔基，2-羟基 - 乙氧基，2-羟乙基氨基甲基，2-氰乙基氨基甲基，吗啉-4-基甲基，甲氧基甲氧基甲基，环丙基，1-氮杂环丁基甲基，1-吡咯烷基甲基， 3-二氧戊环-2-基; R2是氢或卤素; R3是氢或卤素; R2和R3中的至少一个是氢; R4是氢，甲基或卤素; 并且是存在或不存在的单键或其药学上可接受的盐。

5. 发明申请

US20100081641A1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER 失效
标题翻译：用于治疗癌症的咪达唑仑胺氨基嘧啶化合物
公开(公告)号：US20100081641A1
公开(公告)日：2010-04-01
申请号：US12516251
申请日：2007-12-11
申请人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong-Yu Li , Jason Scott Sawyer , Yan Wang
发明人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong-Yu Li , Jason Scott Sawyer , Yan Wang
IPC分类号： A61K31/397 , C07D403/14 , A61K31/506 , C07D413/14 , A61K31/5377 , A61P35/00
CPC分类号： C07D409/14
摘要： The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了被认为具有通过抑制Plk1治疗癌症的临床用途的新型咪唑烷基氨基嘧啶化合物。式（I）其中：R1是氨基甲基，（C1-C3烷基）氨基甲基，二（C1-C2烷基）氨基甲基，N-乙基-N-甲基 - 氨基甲基，1-氨基乙基，1-（（C1-C2烷基）乙基，3,3,3-三氟 - 丙基氨基甲基，乙炔基，2-羟基 - 乙氧基，2-羟乙基氨基甲基，2-氰基乙基氨基甲基，吗啉-4-基甲基，甲氧基甲氧基甲基，环丙基，1-氮杂环丁基甲基，1-吡咯烷基甲基， 3-二氧戊环-2-基; R2为氢或卤素; R3是氢或卤素; R2和R3中的至少一个是氢; R4是氢，甲基或卤素; 并且是存在或不存在的单键或其药学上可接受的盐。

6. 发明授权

US08101628B2 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer 失效
标题翻译：咪唑烷酰氨基嘧啶化合物治疗癌症
公开(公告)号：US08101628B2
公开(公告)日：2012-01-24
申请号：US12516514
申请日：2007-12-11
申请人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong-Yu Li , Melissa Kate Slater , Yan Wang
发明人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong-Yu Li , Melissa Kate Slater , Yan Wang
IPC分类号： C07D401/00
CPC分类号： C07D409/14
摘要： The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了被认为具有通过抑制Plk1治疗癌症的临床用途的新型咪唑烷基氨基嘧啶化合物。其中：R 1氢，羟基，卤素，甲基，C 1 -C 2烷氧基，氨基或甲基氨基; R2是氢，卤素或氰基; R3是氢或卤素; R4是氢，卤素或甲基; 条件是R 1，R 2，R 3和R 4中的至少两个为氢; R5是氢，卤素或甲基; 或其药学上可接受的盐。

7. 发明申请

US20100076001A1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER 失效
标题翻译：用于治疗癌症的咪达唑仑胺氨基嘧啶化合物
公开(公告)号：US20100076001A1
公开(公告)日：2010-03-25
申请号：US12516514
申请日：2007-12-11
申请人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong-Yu Li , Melissa Kate Slater , Yan Wang
发明人： Harold Burns Brooks , Joyce Z. Crich , James Robert Henry , Hong-Yu Li , Melissa Kate Slater , Yan Wang
IPC分类号： A61K31/506 , C07D409/14 , A61P35/04
CPC分类号： C07D409/14
摘要： The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了被认为具有通过抑制Plk1治疗癌症的临床用途的新的咪唑烷基氨基嘧啶化合物。其中：R 1氢，羟基，卤素，甲基，C 1 -C 2烷氧基，氨基或甲基氨基; R2是氢，卤素或氰基; R3是氢或卤素; R4是氢，卤素或甲基; 条件是R 1，R 2，R 3和R 4中的至少两个为氢; R5是氢，卤素或甲基; 或其药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式